We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Kira Pharmaceuticals announced that the first healthy volunteer has been successfully dosed in a first-in-human Phase 1 clinical trial for its lead investigational therapy P014. This randomized, double blind, placebo-controlled study will evaluate the ...